

Anneke Geurts-Moespot

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1168908/publications.pdf>

Version: 2024-02-01

36
papers

1,237
citations

394421

19
h-index

377865

34
g-index

37
all docs

37
docs citations

37
times ranked

1882
citing authors

#	ARTICLE	IF	CITATIONS
1	Prognostic significance of VEGF and components of the plasminogen activator system in endometrial cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2020, 146, 1725-1735.	2.5	6
2	Therapeutic targeting of autophagy in cancer. Part I: Molecular pathways controlling autophagy. <i>Seminars in Cancer Biology</i> , 2015, 31, 89-98.	9.6	47
3	Therapeutic targeting of autophagy in cancer. Part II: Pharmacological modulation of treatment-induced autophagy. <i>Seminars in Cancer Biology</i> , 2015, 31, 99-105.	9.6	69
4	Cetuximab Reduces the Accumulation of Radiolabeled Bevacizumab in Cancer Xenografts without Decreasing VEGF Expression. <i>Molecular Pharmaceutics</i> , 2014, 11, 4249-4257.	4.6	8
5	Role of Endogenous Vascular Endothelial Growth Factor in Endothelium-Dependent Vasodilation in Humans. <i>Hypertension</i> , 2013, 61, 1060-1065.	2.7	50
6	Identification, validation and clinical implementation of cancer biomarkers: Translational strategies of the EORTC PathoBiology Group. <i>European Journal of Cancer, Supplement</i> , 2012, 10, 120-127.	2.2	3
7	Vascular Endothelial Growth Factor in Systemic Capillary Leak Syndrome. <i>American Journal of Medicine</i> , 2009, 122, e5-e7.	1.5	57
8	Components of the plasminogen activator system and their complexes in renal cell and bladder cancer: comparison between normal and matched cancerous tissues. <i>BJU International</i> , 2008, 102, 177-182.	2.5	19
9	PAI-1 levels predict response to fractionated irradiation in 10 human squamous cell carcinoma lines of the head and neck. <i>Radiotherapy and Oncology</i> , 2008, 86, 361-368.	0.6	20
10	Prospective Biomarker Trials Chemo N0 and NNBC-3 Europe Validate the Clinical Utility of Invasion Markers uPA and PAI-1 in Node-Negative Breast Cancer. <i>Breast Care</i> , 2008, 3, 3-3.	1.4	7
11	Association between High Levels of Blood Macrophage Migration Inhibitory Factor, Inappropriate Adrenal Response, and Early Death in Patients with Severe Sepsis. <i>Clinical Infectious Diseases</i> , 2007, 44, 1321-1328.	5.8	98
12	MACROPHAGE MIGRATION INHIBITORY FACTOR (MIF) IN MENINGOCOCCAL SEPTIC SHOCK AND EXPERIMENTAL HUMAN ENDOTOXEMIA. <i>Shock</i> , 2007, 27, 482-487.	2.1	29
13	Complex congenital malformations and the impact of the plasminogen activator system and β -hCG in amniotic fluid. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2007, 135, 47-52.	1.1	5
14	Possible role of the plasminogen activation system in human subfertility. <i>Fertility and Sterility</i> , 2007, 87, 619-626.	1.0	25
15	Induction of plasminogen activator inhibitor type-1 (PAI-1) by hypoxia and irradiation in human head and neck carcinoma cell lines. <i>BMC Cancer</i> , 2007, 7, 143.	2.6	17
16	Serum and BAL macrophage migration inhibitory factor levels in HIV infected Tanzanians with pulmonary tuberculosis or other lung diseases. <i>Clinical Immunology</i> , 2007, 123, 60-65.	3.2	13
17	MIF production by dendritic cells is differentially regulated by Toll-like receptors and increased during rheumatoid arthritis. <i>Cytokine</i> , 2006, 36, 51-56.	3.2	31
18	Concentrations of plasminogen activators and their inhibitors in blood preconceptionally, during and after pregnancy. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2006, 128, 22-28.	1.1	42

#	ARTICLE	IF	CITATIONS
19	Protein chip based miniaturized assay for the simultaneous quantitative monitoring of cancer biomarkers in tissue extracts. <i>Proteomics</i> , 2006, 6, 1427-1436.	2.2	39
20	Effect of Reoxygenation on the Hypoxia-Induced Up-Regulation of Serine Protease Inhibitor PAI-1 in Head and Neck Cancer Cells. <i>Oncology</i> , 2006, 71, 282-291.	1.9	14
21	Correlation of rheumatoid arthritis severity with the genetic functional variants and circulating levels of macrophage migration inhibitory factor. <i>Arthritis and Rheumatism</i> , 2005, 52, 3020-3029.	6.7	203
22	Concerns about Mammaglobin Assays. <i>Clinical Chemistry</i> , 2005, 51, 474-475.	3.2	0
23	The complex between urokinase-type plasminogen activator (uPA) and its type-1 inhibitor (PAI-1) independently predicts response to first-line endocrine therapy in advanced breast cancer. <i>Thrombosis and Haemostasis</i> , 2004, 91, 514-521.	3.4	12
24	Development of an ELISA for Measurement of BCAR1 Protein in Human Breast Cancer Tissue. <i>Clinical Chemistry</i> , 2004, 50, 1356-1363.	3.2	12
25	The Prognostic Value of BCAR1 in Patients with Primary Breast Cancer. <i>Clinical Cancer Research</i> , 2004, 10, 6194-6202.	7.0	51
26	Application of a Newly Developed ELISA for BCAR1 Protein for Prediction of Clinical Benefit of Tamoxifen Therapy in Patients with Advanced Breast Cancer. <i>Clinical Chemistry</i> , 2004, 50, 1445-1447.	3.2	9
27	Complex of urokinase-type plasminogen activator with its type 1 inhibitor predicts poor outcome in 576 patients with lymph node-negative breast carcinoma. <i>Cancer</i> , 2004, 101, 486-494.	4.1	35
28	Ethnic variations in uterine leiomyoma biology are not caused by differences in myometrial estrogen receptor alpha levels. <i>Journal of the Society for Gynecologic Investigation</i> , 2003, 10, 105-109.	1.7	16
29	Vascular endothelial growth factor independently predicts the efficacy of postoperative radiotherapy in node-negative breast cancer patients. <i>Clinical Cancer Research</i> , 2003, 9, 6363-70.	7.0	32
30	Levels of plasminogen activators and their inhibitors in maternal and umbilical cord plasma in severe preeclampsia. <i>American Journal of Obstetrics and Gynecology</i> , 2002, 187, 1019-1025.	1.3	42
31	Evaluation of the efficiency of chemotherapy in in vivo orthotopic models of human glioma cells with and without 1p19q deletions and in C6 rat orthotopic allografts serving for the evaluation of surgery combined with chemotherapy. <i>Cancer</i> , 2002, 95, 641-655.	4.1	104
32	Plasminogen activator system in serum and amniotic fluid of euploid and aneuploid pregnancies. <i>Obstetrics and Gynecology</i> , 2001, 97, 404-408.	2.4	11
33	Vascular endothelial growth factor in ovarian cyst fluid. <i>Cancer</i> , 2001, 91, 371-377.	4.1	29
34	Angiostatin generation by human tumor cell lines: Involvement of plasminogen activators. , 2000, 86, 760-767.		49
35	Scintillation Proximity Assay to Study the Interaction of Epidermal Growth Factor with its Receptor. <i>Journal of Receptors and Signal Transduction</i> , 1992, 12, 389-399.	1.2	6
36	Quality control of cathepsin-D measurement by the EORTC receptor study group. <i>European Journal of Cancer</i> , 1992, 28, 72-75.	2.8	27